Scarica l'app Stockscreener
7.88
1.87%
-0.15
Dopo l'orario di chiusura:
7.88
Precedente Chiudi:
$8.03
Aprire:
$8.24
Volume 24 ore:
1.12M
Relative Volume:
0.59
Capitalizzazione di mercato:
$520.18M
Reddito:
$170.44M
Utile/perdita netta:
$-193.88M
Rapporto P/E:
-2.099
EPS:
-3.7541
Flusso di cassa netto:
$-126.38M
1 W Prestazione:
-9.32%
1M Prestazione:
-26.49%
6M Prestazione:
-2.72%
1 anno Prestazione:
-11.36%
Intervallo 1D:
$7.76
$8.3132
Intervallo di 1 settimana:
$7.6359
$8.75
Portata 52W:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.88 | 563.09M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
510.72 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.17 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
172.94 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
988.20 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.67 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research - Barchart.com
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances - streetwisereports.com
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors - BioBuzz
Regenxbio stock surges on director share purchases By Investing.com - Investing.com Nigeria
Regenxbio stock surges on director share purchases - Investing.com
Why is Regenxbio stock rallying today? - investing.com
REGENXBIO : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
H.C. Wainwright cuts Regenxbio stock price target on clinical hold - investing.com
Regenxbio's FDA Hold Threatens Voucher Windfall, Analysts Slash Targets - finance.biggo.com
Regenxbio Hits Regulatory Roadblock After FDA Puts RGX-121 on Hold - Sahm
REGENXBIO Adds Greg Ciongoli to Board Ahead of Commercial Expansion - citybiz
Regenxbio appoints Greg Ciongoli to board of directors - investing.com
REGENXBIO says FDA places RGX-121 on clinical hold; BLA resubmission not expected soon - TradingView
FDA places clinical hold on Regenxbio’s gene therapy for Hunter Syndrome - The Mighty 790 KFGO
Regenxbio halts BLA resubmission for Hunter syndrome therapy By Investing.com - Investing.com Nigeria
REGENXBIO stock tumbles after FDA clinical hold on MPS II therapy - Investing.com Nigeria
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling - Barron's
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Eastern Progress
REGENXBIO (NASDAQ:RGNX) Trading Down 3.9%Should You Sell? - MarketBeat
RGNX Q2 2026 Earnings: Gene Therapy Developer Posts 626% EPS SurpriseEBITDA Analysis - Vinanet
Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - MarketBeat
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO (RGNX) Pulls Back 2.29% to $10.66 — Gene Therapy Play Tests Key SupportPCR Moving Average - Vinanet
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - MarketBeat
REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK
RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - MarketBeat
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regenxbio Inc Azioni (RGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director |
Aug 26 '26 |
Buy |
9.14 |
49,196 |
449,706 |
64,628 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
7.86 |
2,161 |
16,985 |
215,170 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
0.05%
1.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):